• Je něco špatně v tomto záznamu ?

Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT

E. Forcade, S. Chevret, J. Finke, G. Ehninger, F. Ayuk, D. Beelen, L. Koster, A. Ganser, L. Volin, H. Sengeloev, M. Michallet, J. Tischer, P. Jindra, MJP. Cascon, Y. Koc, M. Arat, A. Tomaszewska, P. Hayden, T. de Witte, I. Yakoub-Agha, N. Kröger, M. Robin

. 2022 ; 57 (5) : 768-774. [pub] 20220226

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018523
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 35220412
DOI 10.1038/s41409-022-01620-x
Knihovny.cz E-zdroje

While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018523
003      
CZ-PrNML
005      
20220804134829.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-022-01620-x $2 doi
035    __
$a (PubMed)35220412
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Forcade, Edouard $u CHU Bordeaux, F-33000, Bordeaux, France $1 https://orcid.org/0000000288732868
245    10
$a Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT / $c E. Forcade, S. Chevret, J. Finke, G. Ehninger, F. Ayuk, D. Beelen, L. Koster, A. Ganser, L. Volin, H. Sengeloev, M. Michallet, J. Tischer, P. Jindra, MJP. Cascon, Y. Koc, M. Arat, A. Tomaszewska, P. Hayden, T. de Witte, I. Yakoub-Agha, N. Kröger, M. Robin
520    9_
$a While in vivo T-cell depletion (TCD) is widely used, its benefit in patients with MDS still remains a matter of debate. This study evaluates the impact of TCD on outcomes, and compares ATG and alemtuzumab, in patients with MDS. 1284 patients from the EBMT registry were included in this study with 470 patients in the no-TCD group and 814 in the TCD group (alemtuzumab N = 168; ATG N = 646). At 6 months, aGVHD III-IV cumulative incidences (CI) for no-TCD, ATG or alemtuzumab groups were 13% vs 14% vs 11% (ns), respectively. At 5 years, CI of chronic GVHD were 64% vs 52% vs 51% (p < 0.00017); and CI of relapse was 23% vs 25% vs 39% (p < 0.0001) for no TCD, ATG and alemtuzumab respectively; OS was 47% vs 46% vs 34% (p = 0.009) respectively; and GRFS was 21% vs 28% and 20% (p = 0.045) respectively. In multivariable analysis, ATG improved GRFS, and alemtuzumab decreased OS. Both ATG and alemtuzumab decreased risk of chronic GVHD, but the increased risk of relapse with alemtuzumab is associated with a poor GRFS and suggest to not use alemtuzumab in the setting of allo-SCT for high risk disease.
650    _2
$a alemtuzumab $x terapeutické užití $7 D000074323
650    12
$a nemoc štěpu proti hostiteli $x etiologie $7 D006086
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a lidé $7 D006801
650    12
$a myelodysplastické syndromy $x komplikace $x terapie $7 D009190
650    12
$a nádory $x komplikace $7 D009369
650    _2
$a recidiva $7 D012008
650    _2
$a registrace $7 D012042
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a T-lymfocyty $7 D013601
650    _2
$a příprava pacienta k transplantaci $x škodlivé účinky $7 D019172
650    _2
$a homologní transplantace $x škodlivé účinky $7 D014184
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chevret, Sylvie $u Hopital Saint-Louis, APHP, Université de Paris, Paris, France
700    1_
$a Finke, Jürgen $u Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
700    1_
$a Ehninger, Gerhard $u Universitaetsklinikum Dresden, Dresden, Germany
700    1_
$a Ayuk, Francis $u University Hospital Eppendorf, Hamburg, Germany
700    1_
$a Beelen, Dietrich $u University Hospital, Essen, Germany
700    1_
$a Koster, Linda $u EBMT Data Office, Leiden, The Netherlands
700    1_
$a Ganser, Arnold $u Hannover Medical School, Hannover, Germany
700    1_
$a Volin, Liisa $u HUCH Comprehensive Cancer Center, Helsinki, Finland
700    1_
$a Sengeloev, Henrik $u Rigshospitalet, Copenhagen, Denmark
700    1_
$a Michallet, Mauricette $u Centre Hospitalier Lyon Sud, Lyon, France
700    1_
$a Tischer, Johanna $u University Hospital, LMU Munich, Department of Medicine III, Munich, Germany
700    1_
$a Jindra, Pavel $u Charles University Hospital, Pilsen, Czech Republic $1 https://orcid.org/0000000284157069
700    1_
$a Cascon, Maria Jesús Pascual $u Hospital Regional de Málaga, Málaga, Spain
700    1_
$a Koc, Yener $u Medical Park Hospitals, Antalya, Turkey
700    1_
$a Arat, Mutlu $u Sisli Florence Nightingale Hospital, Istanbul, Turkey $1 https://orcid.org/0000000320398557
700    1_
$a Tomaszewska, Agnieszka $u Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Hayden, Patrick $u St James Hospital, Dublin, Ireland
700    1_
$a de Witte, Theo $u Radboud University - Nijmegen Medical Centre, Nijmegen, The Netherlands
700    1_
$a Yakoub-Agha, Ibrahim $u CHU de Lille, université de Lille, LIRIC, Inserm U995, 59000, Lille, France $1 https://orcid.org/0000000345248782
700    1_
$a Kröger, Nicolaus $u University Hospital Eppendorf, Hamburg, Germany
700    1_
$a Robin, Marie $u Hopital Saint-Louis, APHP, Université de Paris, Paris, France. marie.robin@aphp.fr $1 https://orcid.org/0000000313889876
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 57, č. 5 (2022), s. 768-774
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35220412 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134823 $b ABA008
999    __
$a ok $b bmc $g 1822219 $s 1169766
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 57 $c 5 $d 768-774 $e 20220226 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace